Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STABIL-NOR semaglutide add-on for metabolic control in antipsychotic-treated schizophrenia-spectrum patients
2023-506109-20-00Phase 3Authorised
- Sponsor
- Helse Bergen
- Start
- Oct 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in obesity, prediabetes and metabolic dysfunction comparing Semaglutide add-on with Placebo add-on (2 arms). Primary endpoint: Change in body weight. Planned start Oct 2024; status: authorised.
02
Drugs
03
Conditions
obesityprediabetesmetabolic dysfunction
Beyond the preview
Go deeper on 2023-506109-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506109-20-00.